Wannan shafin yana aiwatar da ayyuka na asali kuma bai shirya don amfanin marasa lafiya ba tukuna.
Wannan shafin yana aiwatar da ayyuka na asali kuma bai shirya don amfanin marasa lafiya ba tukuna.
Don bayani kawai — ba shawarar likita ba ne
Yaya tsananinsa?
Haɗarin mutuwa
Eh
Allurar rigakafi tana nan?
Lokacin zuwa alamomi
Ƙasashen da abin ya shafa
Annobar da ke gudana
Kyanda tana da saurin yaduwa sosai kuma barkewar cuta tana faruwa a duniya baki daya. Ka tabbatar da yanayin allurar MMR kafin tafiya (ana bukatar allura 2). Matafiya da ba su yi allura ba suna cikin hadari mai girma a wuraren cunkoson jama'a. Yin allurar rigakafi bayan fallasa cikin sa'a 72 yana iya hana cutar.
Kyanda cuta ce mai yaduwa da kwayar cutar paramyxovirus ke haifarwa. Tana yaduwa ta hanyar iska kuma tana iya haifar da matsaloli masu tsanani musamman ga yara.
Alamomi | Yawan faruwa | Tsanani | Farawa |
|---|---|---|---|
| Jan ido | 92% | Dan kadan | Farkon cuta |
| Tari | 95% | Dan kadan | Farkon cuta |
| Zazzabi mai tsanani | 98% | Mai tsanani | Farkon cuta |
| Rashin jin daɗi | 85% | Dan kadan | Farkon cuta |
| Zubar hanci | 90% | Dan kadan | Farkon cuta |
| Ciwon kai | 50% | Dan kadan | Farkon cuta |
| Saurin fushi | 60% | Dan kadan | Farkon cuta |
| Yawan zubar hawaye | 60% | Dan kadan | Farkon cuta |
| Rashin son ci | 70% | Dan kadan | Farkon cuta |
| Rashin jure haske | 50% | Dan kadan | Farkon cuta |
| Ciwon tsoka | 35% | Dan kadan | Farkon cuta |
| Ciwon maƙogwaro | 40% | Dan kadan | Farkon cuta |
| Ƙurji na maculopapular | 99% | Dan kadan | Kololuwar cuta |
| Kumburin ƙwayoyin lymph | 50% | Dan kadan | Kololuwar cuta |
| Ciwon ciki | 20% | Dan kadan | Kololuwar cuta |
| Zawo | 8% | Dan kadan | Kololuwar cuta |
| Amai | 15% | Dan kadan | Kololuwar cuta |
| Gajiya | 80% | Dan kadan | Kowane lokaci |
Measles is a highly contagious viral disease caused by the measles virus (morbillivirus). It remains one of the most communicable infectious diseases, with a reproduction number (R₀) of approximately 12-18, meaning one infected person can spread the virus to up to 18 others in an unvaccinated population. Despite being vaccine-preventable, measles continues to pose risks to travelers visiting regions with lower vaccination coverage.
Measles spreads through:
Airborne droplets: When an infected person coughs or sneezes
Direct contact: With respiratory secretions from infected individuals
High transmissibility: The virus remains infectious in air for up to 2 hours after an infected person leaves a room
Travelers to regions with active measles outbreaks face significant risk, particularly those who are:
Unvaccinated or partially vaccinated
Traveling with unvaccinated children
Born after 1957 without documented vaccination
Incubation Period: 7-21 days (average 10 days)
Classic Presentation (3-phase progression):
Severity: Measles typically causes more severe illness than many other vaccine-preventable diseases, with complications occurring in 1 out of every 4 infected children.
Serious complications occur in approximately 1-2 per 1,000 infected individuals:
Pneumonia (most common complication, ~7% of cases)
Encephalitis (brain inflammation, ~0.1% of cases)
Subacute Sclerosing Panencephalitis (SSPE): Rare but fatal degenerative brain disease occurring 7-10 years after infection
Secondary infections: Otitis media, sinusitis
Mortality: 0.2% in developed countries; up to 10% in low-resource settings with malnutrition
Vaccine Effectiveness:
1 dose: ~95% effective
2 doses: >99% effective
Immunity: Lifelong for vaccinated individuals
Recommended Vaccination:
2 doses of MMR vaccine (measles, mumps, rubella)
First dose: 12-15 months
Second dose: 4-6 years or any time ≥28 days after first dose
Adults born 1957 or later should have ≥2 documented doses or serological proof of immunity
Pre-Travel Considerations:
Verify immunity 4-6 weeks before travel
Request revaccination if immunity status is uncertain
Immunocompromised individuals should consult healthcare providers before vaccination
High-risk destinations: Sub-Saharan Africa, parts of Asia, pockets of low vaccination coverage in developed countries
Outbreak awareness: Check WHO travel advisories and local health departments for current measles activity
Post-exposure guidance: If exposed to measles, vaccinated or unvaccinated individuals should seek medical evaluation immediately
Isolation protocol: Infected travelers should remain isolated for 4 days after rash onset to prevent further transmission
Seek immediate medical attention if experiencing:
High fever (>40°C/104°F) not responding to antipyretics
Difficulty breathing or chest pain
Severe headache or sensitivity to light
Confusion or altered consciousness
Signs of dehydration (no urination for >6 hours, severe thirst)
Diagnosis: Clinical presentation + PCR testing, serology, or viral culture
Treatment: Supportive care (no specific antiviral); vitamin A supplementation recommended
Reportable disease: Measles is notifiable to health authorities in most countries
Causative Agent: Measles morbillivirus
ICD-10 Code: B05
ICD-11 Code: 1F03
Incubation Period: 7-21 days
Infectious Period: 4 days before rash to 4 days after rash onset
Mortality Rate: 0.2-10% depending on healthcare access
Vaccine-Preventable: Yes (highly effective)
Notifiable Disease: Yes (mandatory reporting)
Kyanda (Measles) cuta ce mai tsananin yaduwa da kwayar cutar kyanda (Measles morbillivirus) daga dangin Paramyxoviridae ke haddasa ta. Tana daga cikin cututtukan da suka fi yaduwa a duniya, inda adadin yaduwa na asali (R0) ya kai tsakanin 12 zuwa 18. Tana yaduwa ta hanyar digogin numfashi da hayakin da ake fitarwa idan aka yi atishawa ko tari, kuma kwayar cutar za ta iya rataya a cikin iska har sa'a biyu bayan mai cutar ya bar wuri.
Lokacin da mutum zai iya yada cutar ya faro ne daga kwanaki 4 kafin kuraje su bayyana har zuwa kwanaki 4 bayan sun bayyana. Duk da cewa an samu maganin rigakafi (vaccine) mai inganci tun shekarar 1963, kyanda har yanzu tana daga cikin manyan abubuwan da ke kashe yara wadanda za a iya hana su ta hanyar allurar rigakafi a duniya. Hukumar Lafiya ta Duniya (WHO) ta kiyasta kusan miliyan 10.3 na kamuwa da cutar da mutuwar mutane kusan 107,500 a shekarar 2023.
A Najeriya, kyanda tana daga cikin manyan cututtukan da ke kashe yara musamman a yankin Arewa. Kalubalantar rigakafin yara na yau da kullum (Routine Immunisation — RI) a yankunan Arewacin Najeriya ya sa barkewar cutar ta zama ruwan dare. Hukumar Kula da Cututtuka ta Najeriya (NCDC) tana samun rahotannin dubban shari'o'in da ake zargi a kowace shekara. Shirin Rigakafin Kasa (NPI) da NPHCDA sun hada allurar MMR/MR a cikin jadawalin rigakafin yara. Domin kawar da kyanda, ana bukatar isasshen rigakafi na kashi 95% ko fiye da allurai biyu na MMR.
Kyanda cuta ce da dole a bayar da rahoton ta ga hukumomi a Najeriya da dukan kasashen Yammacin Afirka. Jadawalin rigakafin yara na Najeriya (NPHCDA) ya hada da allura ta farko ta kyanda/MR a wata 9 da kuma allura ta biyu a wata 15.
Nemi kulawar gaggawa nan take idan wadannan suka bayyana:
Wahalar numfashi ko saurin numfashi
Ciwon kai mai tsanani ko taurin wuya ko sauyin wayewar kai (kumburin kwakwalwa)
Farfadiya (seizures)
Rashin iya sha ko amai mara yankewa
Alamun rashin ruwa mai tsanani (idanu masu nutsewa, rashin yin fitsari, gajiya mai tsanani)
Ka kira lambar gaggawa ko ka tafi asibiti mafi kusa nan take.
Alamomi da alamu mafi yawa
Lokacin kwanciyar cuta (Incubation period): Kwanaki 10–14
Matakin farko/Prodromal (kwanaki 2–4):
Zazzabi mai tsanani (zai iya kaiwa 40°C)
Tari mai ci gaba, mura (ciwon hanci), da kumburewar idanu (conjunctivitis) — alamu uku na gargajiya
Tabo'in Koplik (Koplik's spots) — fararen tabo masu shudin launi a cikin bakin kusa da hakora — alamar da ta kebance kyanda, tana bayyana kwana 1–2 kafin kuraje
Tsananin haske a idanu (photophobia), gajiya, rashin son abinci
Matakin kuraje (kwanaki 4–7):
Kuraje masu ja da fari (maculopapular rash) suna farawa a bayan kunnuwa da kan goshi, sannan suna bazu daga kai zuwa jiki har zuwa kafafu cikin kwanaki 3–4
Zazzabi yakan kai matsayinsa mafi girma a lokacin da kuraje suka fara bayyanawa
Kumburin glandin lymph a ko'ina; wani lokaci kumburin saifa (spleen)
Kuraje suna bacewa ta hanyar da suka bayyana tare da fitar fatar jiki kamar kitse
Matakin warwarewa (mako 1–3):
Zazzabi yakan ragu bayan kwanaki 3–4 daga bayyanar kuraje
"Mantawar garkuwar jiki" (immune amnesia) — kwayar cutar tana lalata sel din ajiyan garkuwar jiki da suka rigaya suna jiki, tana kawar da kashi 11–73% na tarin kwayoyin garkuwa (antibodies) (Mina et al., Science 2019)
Sanin alamomi shine mataki na farko don amsa cikin sauri.
Matakan cutar kyanda:
Yaɗuwa: Daga kwanaki 4 kafin zuwa kwanaki 4 bayan bayyanar kuraje. Mafi yawan yaɗuwa a matakin farko. Adadin yaɗuwa na asali (R₀): 12–18 (ɗaya daga cikin cututtukan ɗan adam mafi saurin yaɗuwa).
Yadda ake gano wannan cutar
Gwajin asibiti (Clinical diagnosis): Zazzabi mai tsanani + alamu uku (tari, mura, kumburewar idanu) + kuraje masu ja da fari masu saukowa daga kai a cikin mutum da ba a yi masa allura ba yana nuna kyanda sosai. Tabo'in Koplik sun kebance kyanda.
Tabbatar da dakin gwaje-gwaje (Laboratory confirmation — dole ne):
IgM antibodies na kyanda (ELISA): Tana zama tabbatacciya daga rana ta 3 bayan kuraje. Inganci >90%.
RT-PCR: Daga swab din hanci/makogwaro ko fitsari — gwajin da ya fi dacewa, yana gano nau'in kwayar halitta (genotype).
IgG na lokuta biyu: Karuwa sau ≥4 a cikin samfurori biyu.
Rahoto: Cuta ce da dole a bayar da rahoton ta nan take a Najeriya (NCDC Integrated Disease Surveillance and Response — IDSR).
Hanyoyin magani da ake da su
Magani — tallafin jiki ne kawai (babu maganin kwayar cuta kai tsaye):
Karin Vitamin A (shawarar WHO): IU 200,000 a baki na kwanaki 2 a jere (yara ≥12 wata). Yana rage mutuwa har zuwa kashi 50%. A Najeriya inda rashin abinci mai gina jiki ya yadu, wannan yana da muhimmanci matuka.
Magungunan rage zazzabi (paracetamol ko ibuprofen) — a guji aspirin a yara (Reye syndrome)
Shan ruwa isasshe da abinci mai gina jiki
Magungunan rigakafin kwayoyin cuta (antibiotics) don cututtukan bacteria da suka biyo baya (kamar ciwon kunne, ciwon huhu)
Kwantar da marasa lafiya a asibiti don matsalolin da suka yi tsanani (kumburin kwakwalwa, ciwon huhu, rashin ruwa mai tsanani)
Lura: A Arewacin Najeriya, inda rashin abinci mai gina jiki ya yadu musamman a tsakanin yara, kyanda tana da hatsari sosai — kashi na mutuwa na iya kaiwa 5% ko fiye.
Yawancin lokuta ana magance su yadda ya kamata tare da gano cutar da wuri.
Yadda za ka kare kanka
Allurar rigakafi — matakin da ya fi tasiri:
Allurar MMR (Measles, Mumps, Rubella) tana ba da kariya fiye da 97% bayan allurai biyu.
Jadawalin rigakafin yara na Najeriya (NPHCDA):
Allura ta 1 na MR/Measles: A wata 9
Allura ta 2 na MR/Measles: A wata 15
Kamfen din rigakafin da ake yi a wasu lokutan (Supplementary Immunisation Activities — SIAs)
Kalubale a Najeriya:
Yawan rigakafin allura ta farko a Najeriya: ~60–65% (kasa da matsakaicin duniya)
Arewacin Najeriya: wasu jihohi sun yi kasa da 50%
Dalilai: rashin isassun kayan aikin lafiya, matsalar tsaro, rashin wayar da kai, da wasu imani na addini/al'ada
NPHCDA da abokan hulda suna aiki don inganta rigakafin yau da kullum (RI)
Rigakafi bayan an fuskanci cutar:
Allurar MMR cikin sa'o'i 72 bayan fuskanci cutar
Immunoglobulin cikin kwanaki 6 ga masu hadarin gaske
Bakin garkuwar al'umma (Herd immunity): ~95% da allurai biyu
Shirye-shirye shine mafi kyawun kariya.
Hadarin ga masu tafiya:
Ka tabbatar an yi maka allurai biyu na MMR kafin kowace tafiya zuwa kasashen waje
Hadari mai girma: Afirka ta kudu da Sahara (musamman Najeriya da sauran kasashen Yammacin Afirka), Kudancin da Kudu maso Gabashin Asiya
Masu tafiya zuwa Arewacin Najeriya: hadari na musamman saboda karancin rigakafi
Jarirai masu tafiya zuwa wuraren hadari: ana iya yi wa allurar MMR daga wata 6 ("allura ta sifili")
Ƙididdiga da bayanan yanki
WHO ta kiyasta ~10.3 miliyan na kamuwa da cuta da ~107,500 na mutuwa a 2023. Najeriya tana daga cikin kasashen da suka fi fama da kyanda a duniya — NCDC tana samun rahotannin dubban shari'o'in da ake zargi a kowace shekara, musamman a lokacin rani (Janairu-Mayu). Yankin Arewacin Najeriya (Kano, Kaduna, Katsina, Jigawa, Zamfara, Sokoto) yana da kashi mafi girma saboda karancin yawan rigakafi. Sauran kasashen Yammacin Afirka (Niger, Chadi, Kamaru) ma suna fama da barkewar cutar akai-akai.
Wanene ke cikin haɗarin mafi girma
Risk factors for acquiring measles:
Lack of vaccination: The single most important risk factor. Unvaccinated individuals have a >90% chance of infection after exposure to the virus. Even one missed dose leaves a 7% susceptibility gap.
International travel to endemic regions (sub-Saharan Africa, South/Southeast Asia, parts of Europe) without verified immunity.
Crowded living conditions: Refugee camps, dormitories, military barracks, and densely populated urban areas facilitate rapid transmission.
Healthcare settings: Nosocomial transmission is well-documented; the virus can linger in examination rooms for 2 hours after an infectious patient has left.
Waning maternal antibodies: Infants aged 6–12 months lose maternally acquired protection and are not yet routinely vaccinated.
Community under-vaccination: Localized pockets of low vaccination coverage (religious communities, areas with vaccine hesitancy) serve as outbreak epicenters.
Risk factors for severe disease and complications:
Age extremes: Children under 5 years and adults over 20 years have the highest complication and mortality rates.
Malnutrition: Particularly vitamin A deficiency, which increases the risk of corneal damage, severe pneumonia, and death by 2–3 fold.
Immunocompromised status: HIV/AIDS, active chemotherapy, organ transplant recipients, and congenital immunodeficiencies. These patients may develop giant cell pneumonia (Hecht pneumonia) or measles inclusion body encephalitis (MIBE).
Pregnancy: Measles during pregnancy increases risk of spontaneous abortion, premature delivery, and low birth weight.
Overcrowding and poor access to healthcare: Delayed diagnosis and treatment significantly worsen outcomes.
Rikitarwa da za ta iya faruwa
Matsaloli — sun fi yawa kuma sun fi hatsari a jarirai, masu rashin abinci mai gina jiki, da masu raunin garkuwar jiki:
Ciwon kunne na tsakiya (Otitis media): Matsalar da ta fi yawa (7–9%)
Ciwon huhu (Pneumonia): Babbar sanadin mutuwa daga kyanda (5%)
Kumburin kwakwalwa mai tsanani (Acute post-infectious encephalitis): 1 a cikin 1,000. Kashi na mutuwa 10–15%, raunin kwakwalwa na dindindin a kashi 25%.
Subacute Sclerosing Panencephalitis (SSPE): Cutar kwakwalwa mai kisa da ke bayyanawa bayan shekaru 7–10 daga kamuwa.
Makanta: Saboda rashin Vitamin A da kyanda ta tsananta — matsala ta musamman a Arewacin Najeriya
"Mantawar garkuwar jiki" (Immune amnesia): Lalacewar sel din ajiyan garkuwar jiki na watanni ko shekaru
Mutuwa: Kasashe masu ci gaban masana'antu: 1–2/1,000. Kasashe masu tasowa: 3–5% (na iya kaiwa 30% a tsakanin yawan jama'a masu rashin abinci mai gina jiki). A Arewacin Najeriya, yawan rashin abinci mai gina jiki da rashin samun kulawa ta likita suna sa hadarin mutuwa ya yi yawa.
Sakamakon da ake tsammani da murmurewa
Hasashen warkarwa gabaɗaya: Mai kyau ga mutane masu ingantaccen abinci waɗanda ke da damar samun kulawar lafiya. Adadin mutuwa (CFR) bai wuce 0.1% ba a ƙasashe masu arziki amma ya kai 3–6% a wuraren da ba su da isassun kayan aiki, kuma ya haura zuwa 25% a cikin yara marasa abinci mai gina jiki da al'ummomin da aka raba da muhallansu.
Matsalolin da ke shafar hasashen warkarwa:
Ciwon huhu (babban dalilin mutuwar kyanda): 1–6% na marasa lafiya.
Kumburin ƙwaƙwalwa (encephalitis): ~1 a cikin 1,000; 15% mutuwa, 25% lalacewar jijiyoyin da ba za ta warke ba.
Subacute sclerosing panencephalitis (SSPE): cutar lalacewar tsarin jijiyoyi mai kisa, tana bayyana bayan shekaru 7–10 bayan kamuwa. Yawan faruwa: ~1 a cikin 10,000 na marasa lafiyar kyanda (ya fi yawa idan aka kamu kafin shekara 2).
Mantuwar rigakafi: kyanda na lalata 11–73% na ƙwayoyin rigakafin da ke jiki, wanda ke ƙara haɗarin kamuwa da wasu cututtuka na tsawon shekaru 2–3 bayan warkarwa.
Warkarwa: Mafi yawan marasa rikitarwa suna warke gaba ɗaya cikin kwanaki 7–10. Rigakafi na dindindin bayan kamuwa ta halitta.
Ana iya hana wannan cuta ta hanyar allurar rigakafi. Kariya mai inganci tana samuwa.
Yi magana da ƙwararren lafiyar tafiya game da jadawalin da aka ba da shawarar kafin tafiyar ku.
Nemo asibitin allurar rigakafi →Abun ciki a wannan shafin don bayani da ilimi ne kawai. Ba ya zama shawarar likita, gano cuta, ko shawarwarin magani ba. Idan kuna da damuwar lafiya, tuntuɓi ƙwararren ma’aikacin lafiya. SafeTripVax ba mai ba da sabis na likitanci ba ne.
Cikakkun sharuɗɗan amfaniRecent epidemiological data from the World Health Organization Global Health Observatory.
Source: WHO GHO OData ↗
And 15 more records
This data is provided for informational purposes. Please consult official WHO sources for the most current information.
View WHO data source →Kun san allurar rigakafin da kuke bukata? Da kyau. Ba ku sani ba? Ku gaya mana inda kuke tafiya — za mu nemo allurar da ta dace da asibiti. Kyauta, ba tare da wani hakki ba.